178 related articles for article (PubMed ID: 18852531)
1. Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients.
Attanasio R; Mainolfi A; Grimaldi F; Cozzi R; Montini M; Carzaniga C; Grottoli S; Cortesi L; Albizzi M; Testa RM; Fatti L; De Giorgio D; Scaroni C; Cavagnini F; Loli P; Pagani G; Ghigo E
J Endocrinol Invest; 2008 Aug; 31(8):704-10. PubMed ID: 18852531
[TBL] [Abstract][Full Text] [Related]
2. Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems.
Paisley AN; Roberts ME; Trainer PJ
Clin Endocrinol (Oxf); 2007 May; 66(5):723-6. PubMed ID: 17388793
[TBL] [Abstract][Full Text] [Related]
3. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
Caron P; Morange-Ramos I; Cogne M; Jaquet P
J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
[TBL] [Abstract][Full Text] [Related]
4. Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease?
Cozzi R; Attanasio R; Grottoli S; Pagani G; Loli P; Gasco V; Pedroncelli AM; Montini M; Ghigo E
J Endocrinol Invest; 2004 Dec; 27(11):1040-7. PubMed ID: 15754736
[TBL] [Abstract][Full Text] [Related]
5. Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study.
Brighi N; Lamberti G; Maggio I; Manuzzi L; Ricci C; Casadei R; Santini D; Mosconi C; Lisotti A; Ambrosini V; Pantaleo MA; Campana D
Dig Liver Dis; 2019 May; 51(5):689-694. PubMed ID: 30314949
[TBL] [Abstract][Full Text] [Related]
6. Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients.
Madsen M; Poulsen PL; Orskov H; Møller N; Jørgensen JO
J Clin Endocrinol Metab; 2011 Aug; 96(8):2405-13. PubMed ID: 21632808
[TBL] [Abstract][Full Text] [Related]
7. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
Cozzi R; Attanasio R; Lodrini S; Lasio G
Clin Endocrinol (Oxf); 2004 Aug; 61(2):209-15. PubMed ID: 15272916
[TBL] [Abstract][Full Text] [Related]
8. Fat content in liver and skeletal muscle changes in a reciprocal manner in patients with acromegaly during combination therapy with a somatostatin analog and a GH receptor antagonist: a randomized clinical trial.
Madsen M; Krusenstjerna-Hafstrøm T; Møller L; Christensen B; Vendelbo MH; Pedersen SB; Frystyk J; Jessen N; Hansen TK; Stødkilde-Jørgensen H; Flyvbjerg A; Jørgensen JO
J Clin Endocrinol Metab; 2012 Apr; 97(4):1227-35. PubMed ID: 22298804
[TBL] [Abstract][Full Text] [Related]
9. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly.
Neggers SJ; van Aken MO; Janssen JA; Feelders RA; de Herder WW; van der Lely AJ
J Clin Endocrinol Metab; 2007 Dec; 92(12):4598-601. PubMed ID: 17895318
[TBL] [Abstract][Full Text] [Related]
11. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients.
Neggers SJ; de Herder WW; Janssen JA; Feelders RA; van der Lely AJ
Eur J Endocrinol; 2009 Apr; 160(4):529-33. PubMed ID: 19141604
[TBL] [Abstract][Full Text] [Related]
13. Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center.
Bacigaluppi S; Gatto F; Anania P; Bragazzi NL; Rossi DC; Benvegnu G; Nazzari E; Spaziante R; Giusti M; Ferone D; Zona G
Endocrine; 2016 Mar; 51(3):524-33. PubMed ID: 25982150
[TBL] [Abstract][Full Text] [Related]
14. Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery.
Rubeck KZ; Madsen M; Andreasen CM; Fisker S; Frystyk J; Jørgensen JO
Eur J Endocrinol; 2010 Nov; 163(5):717-26. PubMed ID: 20813787
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study.
Filopanti M; Olgiati L; Mantovani G; Corbetta S; Arosio M; Gasco V; De Marinis L; Martini C; Bogazzi F; Cannavò S; Colao A; Ferone D; Arnaldi G; Pigliaru F; Peri A; Angeletti G; Jaffrain-Rea ML; Lania AG; Spada A
J Clin Endocrinol Metab; 2012 Feb; 97(2):E165-72. PubMed ID: 22162472
[TBL] [Abstract][Full Text] [Related]
16. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly.
Gatto F; Feelders RA; van der Pas R; Kros JM; Waaijers M; Sprij-Mooij D; Neggers SJ; van der Lelij AJ; Minuto F; Lamberts SW; de Herder WW; Ferone D; Hofland LJ
J Clin Endocrinol Metab; 2013 Jan; 98(1):E66-71. PubMed ID: 23118420
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy.
Marazuela M; Lucas T; Alvarez-Escolá C; Puig-Domingo M; de la Torre NG; de Miguel-Novoa P; Duran-Hervada A; Manzanares R; Luque-Ramírez M; Halperin I; Casanueva FF; Bernabeu I
Eur J Endocrinol; 2009 Apr; 160(4):535-42. PubMed ID: 19147599
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
Giusti M; Gussoni G; Cuttica CM; Giordano G
J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
[TBL] [Abstract][Full Text] [Related]
19. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3.
Casarini AP; Pinto EM; Jallad RS; Giorgi RR; Giannella-Neto D; Bronstein MD
J Endocrinol Invest; 2006 Oct; 29(9):826-30. PubMed ID: 17114915
[TBL] [Abstract][Full Text] [Related]
20. McCune-Albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and/or pegvisomant in somatostatin analog-resistant patients.
Galland F; Kamenicky P; Affres H; Reznik Y; Pontvert D; Le Bouc Y; Young J; Chanson P
J Clin Endocrinol Metab; 2006 Dec; 91(12):4957-61. PubMed ID: 16984995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]